A Canadian biotechnology company is negotiating for rights to market a mammography computer-aided diagnosis (CAD) workstation under development in the U.S. The workstation is scheduled to be introduced as a work-in-progress at this year's Radiological
A Canadian biotechnology company is negotiating for rights to market a mammography computer-aided diagnosis (CAD) workstation under development in the U.S. The workstation is scheduled to be introduced as a work-in-progress at this year's Radiological Society of North America meeting.
Qualia Computing of Beavercreek, OH, is developing the workstation, called CADx. The system is designed to provide a backup to mammographers by identifying microcalcifications and suspicious images. CADx employs image enhancement techniques and neural network software. Many of the Qualia engineers working on the project have experience developing pattern recognition systems for the U.S. Air Force Institute of Technology (AFIT) at Wright Patterson Air Force Base in Dayton, OH.
Qualia has reached an agreement-in-principle to license exclusive rights to CADx to Briana Bio-Tech of Edmonton, Alberta. Briana has agreed to fund development of CADx and provide royalty and milestone payments.
When the workstation reaches the market, it could become a competitor to systems being developed by firms such as Scanis of Mountain View, CA, and R2 Technology of Los Altos, CA. R2 began European sales of its ImageChecker system earlier this year (SCAN 4/16/97).
Computed Tomography Study Assesses Model for Predicting Recurrence of Non-Small Cell Lung Cancer
January 31st 2025A predictive model for non-small cell lung cancer (NSCLC) recurrence, based on clinical parameters and CT findings, demonstrated an 85.2 percent AUC and 83.3 percent sensitivity rate, according to external validation testing in a new study.